Pharmaceutical research team working in a modern facility

Pharmaceutical industry news

Fresh coverage across pharma, biotech, medtech, research, approvals, and market-moving developments.

39,835 stories, page 347 of 664

Advanced search

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT07523750: A Study of VARIPULSE Pulsed Field Ablation (PFA) Catheter and FARAWAVE PFA Catheter in the Treatment of Participants With Persistent Atrial Fibrillation

Study type: INTERVENTIONAL. Phase: NA.

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT07520461: Microbiome-targeted Diet Therapy in Ulcerative Colitis

Study type: INTERVENTIONAL. Phase: NA.

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT07479576: A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2106 vs Tremfye® in Healthy Subjects

Study type: INTERVENTIONAL. Phase: PHASE1.

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT07349121: OPTION-EMEA Clinical Trial

Study type: INTERVENTIONAL. Phase: NA.

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT07294924: Prediction of REsponse to Depression Interventions (Accelerated rTMS) Using Clinical and TD-fNIRS Measurements

Study type: OBSERVATIONAL. Phase: .

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT07293247: A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

Study type: INTERVENTIONAL. Phase: PHASE2.

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT07215910: Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

Study type: INTERVENTIONAL. Phase: PHASE3.

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT07153146: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects.

Study type: INTERVENTIONAL. Phase: PHASE1.

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT07098286: Enhancing Resilience Among Patients With Stroke: Implementation of High Intensity Home-based Rehabilitation

Study type: OBSERVATIONAL. Phase: .

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT06816108: A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors

Study type: INTERVENTIONAL. Phase: PHASE1.

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT06800196: A Study of KNT-0916 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

Study type: INTERVENTIONAL. Phase: PHASE1.

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT06770660: Effect of Tele-exercise on Cardiorespiratory Fitness in Paediatrics

Study type: INTERVENTIONAL. Phase: NA.

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT06730113: Youth-Onset Type 2 Diabetes and Heart Disease: The Young at Heart Prospective Cohort Study

Study type: OBSERVATIONAL. Phase: .

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT06669247: A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma

Study type: INTERVENTIONAL. Phase: PHASE1, PHASE2.

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT06632977: Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

Study type: INTERVENTIONAL. Phase: PHASE2.

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT06568861: A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

Study type: INTERVENTIONAL. Phase: PHASE1.

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT06401928: Electrical Brain Stimulation for Treatment of Secondary Symptoms in Multiple Sclerosis

Study type: INTERVENTIONAL. Phase: NA.

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT06379789: A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

Study type: INTERVENTIONAL. Phase: PHASE1, PHASE2.

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT06238466: A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia

Study type: INTERVENTIONAL. Phase: PHASE1.

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT06232044: Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

Study type: INTERVENTIONAL. Phase: PHASE1, PHASE2.

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Study type: INTERVENTIONAL. Phase: PHASE3.

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT06108089: Novel Hypoxia Imaging for Head and Neck Cancer: Imaging Phenotype for Personalized Treatment

Study type: OBSERVATIONAL. Phase: .

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT05849207: Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant

Study type: INTERVENTIONAL. Phase: PHASE1.

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT05708352: A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment

Study type: INTERVENTIONAL. Phase: PHASE2.

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT05701800: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age

Study type: INTERVENTIONAL. Phase: PHASE1.

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT05583617: A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

Study type: INTERVENTIONAL. Phase: PHASE1, PHASE2.

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT04417283: Project HOPE 1000: Health Outcomes Pregnancy Exposures

Study type: OBSERVATIONAL. Phase: .

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT03459846: A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

Study type: INTERVENTIONAL. Phase: PHASE2.

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT02494869: Dose-Response of Aerobic Training in Women at High-Risk for Development of Breast Cancer

Study type: INTERVENTIONAL. Phase: NA.

ClinicalTrials.govOriginal source

🇺🇸Aug 5Researchclinicaltrials.govTier 1 · Trial registry

NCT00911560: Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

Study type: INTERVENTIONAL. Phase: PHASE1, PHASE2.

ClinicalTrials.govOriginal source

🌍Aug 5discoverynews.google.comTier 3 · Aggregated media

Walking the Line: Navigating AKS Risk in Pharmaceutical Speaker Programs and Patient Support

The National Law ReviewOriginal source

🌍Aug 5discoverynews.google.comTier 3 · Aggregated media

Young Chairs Hearing on American Biotechnology Leadership, Building a Resilient Health Care Future

Senator Young (.gov)Original source

🌍Aug 5discoverynews.google.comTier 3 · Aggregated media

Biotech Founder Claims He Was Excluded From GSK Deal

Law360Original source

🌍Aug 5discoverynews.google.comTier 3 · Aggregated media

Enterprise value to revenue forward of KINTOR PHARMACEUTICAL LTD. – OTC:KNTPF

TradingViewOriginal source

🌍Aug 5discoverynews.google.comTier 3 · Aggregated media

FDA Stance on CBD Gummies 2025 Regulations - View hUixU0MbM

Diario ASOriginal source

🌍Aug 5discoverynews.google.comTier 3 · Aggregated media

Is CBD Gummies a Drug? - View NyS2eSXCL

Diario ASOriginal source

🌍Aug 5discoverynews.google.comTier 3 · Aggregated media

ETFs Investing in Chugai Pharmaceutical Co., Ltd. Unsponsored ADR Stocks

TradingViewOriginal source

🌍Aug 5discoverynews.google.comTier 3 · Aggregated media

FDA Warnings Slimming Tea Sibutramine: Why These Products Pose Serious Health Risks and How to Stay Safe ZFRa7D0tL

FC BayernOriginal source

🌍Aug 5discoverynews.google.comTier 3 · Aggregated media

Ono Pharmaceutical Co., Ltd. 2027 Q1 - Results - Earnings Call Presentation (OTCMKTS:OPHLY) 2026-08-04

Seeking AlphaOriginal source

🌍Aug 5discoverynews.google.comTier 3 · Aggregated media

Ultragenyx Pharmaceutical Inc reports results for the quarter ended June 30 - Earnings Summary

TradingViewOriginal source

🌍Aug 5discoverynews.google.comTier 3 · Aggregated media

FDA voucher could put Arrowhead's planned drug filing on a six-month review track

Stock TitanOriginal source

🌍Aug 5discoverynews.google.comTier 3 · Aggregated media

Marijuana Industry Is Drowning In Confusion: Why Is Industry Now Demanding Hemp Standards It Never Applied to Itself

newswire.comOriginal source

🌍Aug 5discoverynews.google.comTier 3 · Aggregated media

BioMarin Pharmaceutical Inc expected to post earnings of 69 cents a share - Earnings Preview

TradingViewOriginal source

🌍Aug 5discoverynews.google.comTier 3 · Aggregated media

Price to earnings forward of EOM Pharmaceutical Holdings Inc. – OTC:IMUC

TradingViewOriginal source

🌍Aug 5discoverynews.google.comTier 3 · Aggregated media

Houston's End-to-End Biotech Ecosystem Takes Center Stage at the Future of Biotech Expo

Greater Houston PartnershipOriginal source

🌍Aug 5discoverynews.google.comTier 3 · Aggregated media

Price to book forward of KINTOR PHARMACEUTICAL LTD. – OTC:KNTPF

TradingViewOriginal source

🌍Aug 5discoverynews.google.comTier 3 · Aggregated media

Edesa Biotech (NASDAQ: EDSA) CEO receives 5,324 restricted share units

Stock TitanOriginal source

🌍Aug 5discoverynews.google.comTier 3 · Aggregated media

South Korea’s drug regulator appeals JointStem ruling, testing approval system - CHOSUNBIZ

ChosunbizOriginal source

🇺🇸Aug 5Researchfrazierls.comTier 2 · Direct publisher

Attovia Therapeutics Announces Pricing of Upsized Initial Public Offering

Frazier Life SciencesOriginal source

🌍Aug 5discoverynews.google.comTier 3 · Aggregated media

Gilead Sciences Swings to Loss on R&D Costs as HIV-Drug Sales Lift Revenue

WSJOriginal source

🌍Aug 5discoverynews.google.comTier 3 · Aggregated media

IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery

manilatimes.netOriginal source

🌍Aug 5discoverynews.google.comTier 2 · Trade media

Pathos Picks Up Two Cancer Drugs Poised for Clinical Development With AI Agents

MedCity NewsOriginal source

🌍Aug 5discoverynews.google.comTier 3 · Aggregated media

Rigel Reports Second Quarter 2026 Financial Results

TradingViewOriginal source

🌍Aug 5discoverynews.google.comTier 3 · Aggregated media

New autologous T cell therapy offers hope for children with brain tumors

Drug Discovery NewsOriginal source

🌍Aug 5discoverynews.google.comTier 3 · Aggregated media

Eli Lilly will offer experimental obesity drug early to some patients. Who qualifies?

Houston ChronicleOriginal source

🌍Aug 5discoverynews.google.comTier 3 · Aggregated media

FDA Approval for Slimming Teas Weight Loss: What It Really Means and How to Use It Safely ET5mPnnbn

Diario ASOriginal source

🌍Aug 5discoverynews.google.comTier 3 · Aggregated media

Xencor faces earnings test after revenue miss rocks biotech By Investing.com

Investing.com NigeriaOriginal source

🌍Aug 5discoverynews.google.comTier 3 · Aggregated media

A Philadelphia-Area Biotech Just Got the Green Light for a Genomics-Guided Endometriosis Trial in the UAE

biobuzz.ioOriginal source

🌍Aug 5discoverynews.google.comTier 3 · Aggregated media

Pathos AI Enters Two lIcensing Deals | PharmExec

pharmexec.comOriginal source

🇪🇺Aug 5Researchcordis.europa.euTier 2 · Direct publisher

CORDIS project: Lipids as promising BRidge between novel disease InsiGHts and improved Therapy

CORDISOriginal source

Pharmaceutical industry news

NCT07523750: A Study of VARIPULSE Pulsed Field Ablation (PFA) Catheter and FARAWAVE PFA Catheter in the Treatment of Participants With Persistent Atrial Fibrillation

NCT07520461: Microbiome-targeted Diet Therapy in Ulcerative Colitis

NCT07479576: A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2106 vs Tremfye® in Healthy Subjects

NCT07349121: OPTION-EMEA Clinical Trial

NCT07294924: Prediction of REsponse to Depression Interventions (Accelerated rTMS) Using Clinical and TD-fNIRS Measurements

NCT07293247: A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

NCT07215910: Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

NCT07153146: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects.

NCT07098286: Enhancing Resilience Among Patients With Stroke: Implementation of High Intensity Home-based Rehabilitation

NCT06816108: A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumors

NCT06800196: A Study of KNT-0916 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterations

NCT06770660: Effect of Tele-exercise on Cardiorespiratory Fitness in Paediatrics

NCT06730113: Youth-Onset Type 2 Diabetes and Heart Disease: The Young at Heart Prospective Cohort Study

NCT06669247: A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT06632977: Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

NCT06568861: A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic Impairment and in Healthy Subjects With Normal Hepatic Function

NCT06401928: Electrical Brain Stimulation for Treatment of Secondary Symptoms in Multiple Sclerosis

NCT06379789: A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B

NCT06238466: A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia

NCT06232044: Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myeloma

NCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

NCT06108089: Novel Hypoxia Imaging for Head and Neck Cancer: Imaging Phenotype for Personalized Treatment

NCT05849207: Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant

NCT05708352: A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatment

NCT05701800: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Age

NCT05583617: A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma

NCT04417283: Project HOPE 1000: Health Outcomes Pregnancy Exposures

NCT03459846: A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)

NCT02494869: Dose-Response of Aerobic Training in Women at High-Risk for Development of Breast Cancer

NCT00911560: Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma

Walking the Line: Navigating AKS Risk in Pharmaceutical Speaker Programs and Patient Support

Young Chairs Hearing on American Biotechnology Leadership, Building a Resilient Health Care Future

Biotech Founder Claims He Was Excluded From GSK Deal

Enterprise value to revenue forward of KINTOR PHARMACEUTICAL LTD. – OTC:KNTPF

FDA Stance on CBD Gummies 2025 Regulations - View hUixU0MbM

Is CBD Gummies a Drug? - View NyS2eSXCL

ETFs Investing in Chugai Pharmaceutical Co., Ltd. Unsponsored ADR Stocks

FDA Warnings Slimming Tea Sibutramine: Why These Products Pose Serious Health Risks and How to Stay Safe *ZFRa7D0tL*

Ono Pharmaceutical Co., Ltd. 2027 Q1 - Results - Earnings Call Presentation (OTCMKTS:OPHLY) 2026-08-04

Ultragenyx Pharmaceutical Inc reports results for the quarter ended June 30 - Earnings Summary

FDA voucher could put Arrowhead's planned drug filing on a six-month review track

Marijuana Industry Is Drowning In Confusion: Why Is Industry Now Demanding Hemp Standards It Never Applied to Itself

BioMarin Pharmaceutical Inc expected to post earnings of 69 cents a share - Earnings Preview

Price to earnings forward of EOM Pharmaceutical Holdings Inc. – OTC:IMUC

Houston's End-to-End Biotech Ecosystem Takes Center Stage at the Future of Biotech Expo

Price to book forward of KINTOR PHARMACEUTICAL LTD. – OTC:KNTPF

Edesa Biotech (NASDAQ: EDSA) CEO receives 5,324 restricted share units

South Korea’s drug regulator appeals JointStem ruling, testing approval system - CHOSUNBIZ

Attovia Therapeutics Announces Pricing of Upsized Initial Public Offering

Gilead Sciences Swings to Loss on R&D Costs as HIV-Drug Sales Lift Revenue

IQVIA and Medera to Advance Cardiac Gene Therapy and Human-Based Drug Discovery

Pathos Picks Up Two Cancer Drugs Poised for Clinical Development With AI Agents

Rigel Reports Second Quarter 2026 Financial Results

New autologous T cell therapy offers hope for children with brain tumors

Eli Lilly will offer experimental obesity drug early to some patients. Who qualifies?

FDA Approval for Slimming Teas Weight Loss: What It Really Means and How to Use It Safely *ET5mPnnbn*

Xencor faces earnings test after revenue miss rocks biotech By Investing.com

A Philadelphia-Area Biotech Just Got the Green Light for a Genomics-Guided Endometriosis Trial in the UAE

Pathos AI Enters Two lIcensing Deals | PharmExec

CORDIS project: Lipids as promising BRidge between novel disease InsiGHts and improved Therapy

FDA Warnings Slimming Tea Sibutramine: Why These Products Pose Serious Health Risks and How to Stay Safe ZFRa7D0tL

FDA Approval for Slimming Teas Weight Loss: What It Really Means and How to Use It Safely ET5mPnnbn